{"id":14741,"date":"2026-11-09T08:00:00","date_gmt":"2026-11-09T07:00:00","guid":{"rendered":"https:\/\/www.msd.ch\/de\/?post_type=news_item&#038;p=14741"},"modified":"2026-11-05T11:29:50","modified_gmt":"2026-11-05T10:29:50","slug":"zulassung-fuer-keytruda-als-1l-monotherapie-bei-hnscc","status":"publish","type":"news_item","link":"https:\/\/www.msd.ch\/de\/news\/zulassung-fuer-keytruda-als-1l-monotherapie-bei-hnscc\/","title":{"rendered":"Swissmedic erteilt Zulassung f\u00fcr KEYTRUDA\u00ae (Pembrolizumab) als Monotherapie in der Erstlinienbehandlung von Erwachsenen mit metastasiertem oder nicht resezierbarem, rezidivierendem Plattenepithelkarzinom der Kopf-Hals-Region (HNSCC) mit CPS \u2265 1."},"content":{"rendered":"","protected":true},"excerpt":{"rendered":"","protected":true},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"footnotes":""},"tags":[30],"class_list":["post-14741","news_item","type-news_item","status-publish","post-password-required","hentry","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae bei HNSCC | MSD<\/title>\n<meta name=\"description\" content=\"Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae als 1L-Monotherapie bei Erwachsenen mit metastasiertem oder nicht resezierbarem, rezidivierendem HNSCC mit CPS \u2265 1.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/de\/news\/zulassung-fuer-keytruda-als-1l-monotherapie-bei-hnscc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae bei HNSCC | MSD\" \/>\n<meta property=\"og:description\" content=\"Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae als 1L-Monotherapie bei Erwachsenen mit metastasiertem oder nicht resezierbarem, rezidivierendem HNSCC mit CPS \u2265 1.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/de\/news\/zulassung-fuer-keytruda-als-1l-monotherapie-bei-hnscc\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/news\\\/zulassung-fuer-keytruda-als-1l-monotherapie-bei-hnscc\\\/\",\"url\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/news\\\/zulassung-fuer-keytruda-als-1l-monotherapie-bei-hnscc\\\/\",\"name\":\"Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae bei HNSCC | MSD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/#website\"},\"datePublished\":\"2026-11-09T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/news\\\/zulassung-fuer-keytruda-als-1l-monotherapie-bei-hnscc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/\",\"name\":\"msd.ch\",\"description\":\"MSD erforscht und entwickelt Medikamente und Impfstoffe, die Leben retten und die Gesundheit von Patienten verbessern sollen. In der Schweiz setzen sich 1000 Mitarbeitende in Luzern und Z\u00fcrich daf\u00fcr ein.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae bei HNSCC | MSD","description":"Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae als 1L-Monotherapie bei Erwachsenen mit metastasiertem oder nicht resezierbarem, rezidivierendem HNSCC mit CPS \u2265 1.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/de\/news\/zulassung-fuer-keytruda-als-1l-monotherapie-bei-hnscc\/","og_locale":"en_US","og_type":"article","og_title":"Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae bei HNSCC | MSD","og_description":"Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae als 1L-Monotherapie bei Erwachsenen mit metastasiertem oder nicht resezierbarem, rezidivierendem HNSCC mit CPS \u2265 1.","og_url":"https:\/\/www.msd.ch\/de\/news\/zulassung-fuer-keytruda-als-1l-monotherapie-bei-hnscc\/","og_site_name":"msd.ch","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/de\/news\/zulassung-fuer-keytruda-als-1l-monotherapie-bei-hnscc\/","url":"https:\/\/www.msd.ch\/de\/news\/zulassung-fuer-keytruda-als-1l-monotherapie-bei-hnscc\/","name":"Swissmedic-Zulassung f\u00fcr KEYTRUDA\u00ae bei HNSCC | MSD","isPartOf":{"@id":"https:\/\/www.msd.ch\/de\/#website"},"datePublished":"2026-11-09T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.msd.ch\/de\/news\/zulassung-fuer-keytruda-als-1l-monotherapie-bei-hnscc\/#breadcrumb"},"inLanguage":"en-US"},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/de\/#website","url":"https:\/\/www.msd.ch\/de\/","name":"msd.ch","description":"MSD erforscht und entwickelt Medikamente und Impfstoffe, die Leben retten und die Gesundheit von Patienten verbessern sollen. In der Schweiz setzen sich 1000 Mitarbeitende in Luzern und Z\u00fcrich daf\u00fcr ein.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item\/14741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":8,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item\/14741\/revisions"}],"predecessor-version":[{"id":14754,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item\/14741\/revisions\/14754"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/media?parent=14741"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/tags?post=14741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}